The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease (MAFLD)

Inclusion Criteria:

• Patients of both sexes aged 18 to 75 years, who are citizens of the Republic of Kazakhstan;
• Patients with a clinically and laboratory confirmed diagnosis of MAFLD, without severe concomitant diseases;
• Patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others);
• Patients who have at least a 7-day gap between the end of other adjuvant therapy and the start of COC and BDD;
• Patients who voluntarily signed the informed consent form.

Exclusion Criteria:

• Patients who abuse alcohol according to the AUDIT-c questionnaire;
• Patients taking COC for more than 4 weeks before signing the informed consent;
• Patients with contraindications to COC;
• Patients diagnosed with diabetes mellitus;
• Pregnancy and lactation;
• Simultaneous use of levodopa, altretamine, cisplatin, statins;
• Patients with coinfection with HIV, HBV, HCV;
• Decompensated liver cirrhosis CPT≥7 points;
• GFR ≤ 15 ml/min/1.73 m2;
• Drug-induced liver damage;
• Taking narcotic and psychotropic drugs;
• Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than >5 times;
• patients with pronounced biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 ULN;
• Participation in an interventional clinical trial.

Persons aged ≥18 to 75 years inclusive with a diagnosis of metabolic-associated fatty liver disease who are undergoing outpatient monitoring at the place of residence.